Alprostadil (Caverject/MUSE) and Levothyroxine Interaction

Why This Drug Pair Comes Up

Men with hypothyroidism who also have erectile dysfunction (ED) commonly take levothyroxine daily while using alprostadil as needed for refractory ED. The question is reasonable because levothyroxine is notoriously sensitive to absorption interference from co-administered drugs and supplements 1. Proton pump inhibitors, calcium supplements, iron salts, and even coffee can reduce levothyroxine bioavailability by 20% to 40% 2. Patients on thyroid replacement understandably worry about adding any medication.

The short answer: alprostadil does not share any of the mechanisms that cause these absorption problems. It bypasses the GI tract entirely. Caverject is injected directly into the corpus cavernosum, and MUSE is inserted as a pellet into the urethra 3. Neither formulation enters the stomach, small intestine, or hepatic portal system at meaningful concentrations. That distinction removes the most common interaction pathway for levothyroxine.

Pharmacokinetic Profile of Alprostadil

Alprostadil is synthetic prostaglandin E1 (PGE1). After intracavernosal injection, systemic absorption is minimal and localized. The FDA label for Caverject reports that 96% of a radiolabeled dose is recovered in metabolite form within 24 hours, with 80% cleared during a single pulmonary transit 3. The circulating half-life is estimated at under 30 seconds 4.

Metabolism occurs primarily through beta-oxidation and omega-oxidation of the fatty acid side chains in the lungs, not through hepatic cytochrome P450 enzymes 3. Alprostadil is not a substrate, inhibitor, or inducer of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. It is also not a significant P-glycoprotein substrate 5.

This metabolic profile means alprostadil cannot alter the hepatic processing of levothyroxine or compete for shared enzyme pathways. The two drugs exist in functionally separate pharmacokinetic compartments.

Pharmacokinetic Profile of Levothyroxine

Levothyroxine (T4) is absorbed primarily in the jejunum and upper ileum, with bioavailability ranging from 40% to 80% depending on formulation and GI conditions 6. The American Thyroid Association (ATA) recommends taking levothyroxine on an empty stomach, 30 to 60 minutes before breakfast, to maximize consistent absorption 7.

Once absorbed, T4 is highly protein-bound (99.97%) to thyroxine-binding globulin (TBG), transthyretin, and albumin. Deiodination to T3 occurs in the liver, kidneys, and peripheral tissues via type 1 and type 2 deiodinase enzymes 8. These deiodinase pathways are distinct from the CYP system. T4 does undergo some glucuronidation and sulfation via hepatic UGT enzymes, and drugs that induce these pathways (such as phenobarbital, rifampin, or carbamazepine) can increase T4 clearance 7. Alprostadil has no known effect on UGT enzymes or deiodinase activity.

The drugs most likely to disrupt levothyroxine are those that alter gastric pH, bind T4 in the gut lumen, or induce hepatic conjugation. Alprostadil does none of these.

Pharmacodynamic Considerations

Even without a pharmacokinetic overlap, could these drugs interact at the receptor or physiologic level? Alprostadil works by activating EP2 and EP4 prostaglandin receptors on cavernosal smooth muscle, triggering cAMP-mediated relaxation and penile erection 9. Levothyroxine replaces deficient thyroid hormone, acting through nuclear thyroid hormone receptors (TR-alpha and TR-beta) to regulate gene transcription across virtually every tissue 10.

These receptor systems do not overlap. No published evidence demonstrates a PGE1-thyroid hormone receptor crosstalk that would amplify or blunt either drug's clinical effect 5.

One theoretical consideration: both drugs can independently affect blood pressure. Alprostadil causes local vasodilation and, in rare cases, mild systemic hypotension (reported in 2% of Caverject users at the 20 mcg dose) 3. Hypothyroidism itself is associated with diastolic hypertension, and levothyroxine treatment may reduce diastolic pressure by 5 to 10 mmHg as thyroid levels normalize 11. These hemodynamic effects operate through independent mechanisms (prostaglandin-mediated vasodilation vs. thyroid-mediated vascular resistance normalization) and would not be expected to cause clinically relevant additive hypotension. Monitoring is not required beyond standard follow-up.

What the DDI Databases Say

Major drug-drug interaction databases, including Lexicomp, Micromedex, and the FDA Adverse Event Reporting System (FAERS), do not list a clinically significant interaction between alprostadil and levothyroxine 12. The FDA labels for both Caverject and Synthroid/Levoxyl do not cross-reference one another in their drug interaction sections 3 13.

The Caverject label specifically warns about concomitant use with anticoagulants (increased bruising risk at the injection site) and other vasoactive agents for ED (risk of prolonged erection) 3. Levothyroxine is not mentioned. The Synthroid label flags warfarin, digoxin, antidiabetics, and estrogen-containing products as interacting drugs 13. Alprostadil is absent from that list.

This absence is meaningful. Both drugs have been on the market for decades (levothyroxine since 1955, intracavernosal alprostadil since FDA approval in 1995), and no signal of an interaction has emerged from post-marketing surveillance 12.

Thyroid Dysfunction and Erectile Dysfunction: The Clinical Overlap

The reason these two drugs appear in the same medication list is the well-documented link between thyroid disease and sexual dysfunction. A 2008 study by Carani et al. (N=48) found that 64% of hypothyroid men reported ED, with 50% also reporting delayed ejaculation. After thyroid hormone normalization with levothyroxine, IIEF-5 scores improved significantly (mean increase 4.1 points, p<0.001) 14.

A 2018 meta-analysis in Sexual Medicine Reviews confirmed the bidirectional relationship, showing that both hypo- and hyperthyroidism impair erectile function through disrupted sex hormone-binding globulin (SHBG) levels, altered testosterone bioavailability, and direct effects on smooth muscle relaxation 15. The European Association of Urology (EAU) guidelines recommend checking TSH in all men presenting with ED, particularly those with refractory symptoms 16.

For men whose ED persists despite achieving euthyroid status on levothyroxine, alprostadil is a second-line option. The EAU guidelines position intracavernosal injection therapy as appropriate when PDE5 inhibitors fail, with efficacy rates of 70% to 90% regardless of etiology 16.

Dose Timing and Practical Guidance

No special timing protocol is needed for this combination. Standard best practices for each drug individually are sufficient.

For levothyroxine: take on an empty stomach with water, 30 to 60 minutes before the first meal. Avoid calcium, iron, and antacids within 4 hours 7. If consistent morning dosing is difficult, bedtime dosing (at least 3 hours after the last meal) is an acceptable alternative that may actually improve absorption 17.

For alprostadil: use as needed, typically 5 to 40 mcg intracavernosal (Caverject) or 125 to 1 to 000 mcg intraurethral (MUSE), no more than three times per week with at least 24 hours between doses 3. Timing relative to levothyroxine is irrelevant because there is no GI absorption competition.

If a patient is taking other medications that do interact with levothyroxine (e.g., calcium, ferrous sulfate, PPIs), those spacing rules still apply. Alprostadil does not change or complicate the existing levothyroxine timing regimen.

Monitoring Recommendations

For the combination specifically, no additional monitoring is needed beyond what each drug requires independently 7 3.

For levothyroxine: check TSH 6 to 8 weeks after any dose change, then every 6 to 12 months once stable. Free T4 if TSH is discordant with symptoms 7.

For alprostadil: the prescribing physician should perform in-office dose titration before self-injection begins. Periodic assessment for penile fibrosis (reported in 3% to 8% of Caverject users over 18 months of use) is recommended at follow-up visits 3.

If a patient on stable levothyroxine adds alprostadil and subsequently notices fatigue, weight changes, or other thyroid-related symptoms, the cause is not the alprostadil. Recheck TSH to rule out thyroid dose drift, seasonal variation, or a change in another interacting drug 18.

When to Involve Your Physician

While the alprostadil-levothyroxine combination itself is safe, the clinical picture that puts a patient on both drugs warrants a broader medication review. Men with hypothyroidism and refractory ED often take multiple medications (statins, antihypertensives, antidepressants, PDE5 inhibitors) that each carry their own interaction profiles. Anticoagulants deserve particular attention if alprostadil injection is planned, as the risk of penile hematoma increases 3.

Any man using alprostadil who experiences an erection lasting longer than 4 hours should treat it as a medical emergency requiring aspiration or phenylephrine injection, regardless of thyroid status or other medications 16. Priapism risk with alprostadil is dose-dependent and estimated at 1% to 4% in clinical trials 3.

TSH should be rechecked if PDE5 inhibitors are added to the regimen, not because of a direct PDE5-thyroid interaction, but because sildenafil and tadalafil are metabolized by CYP3A4, and thyroid status influences CYP3A4 expression 19.